Lonza selected Cellectis bioresearch to help develop and commercialize a bioengineered cell line. Cellectis will use its meganuclease technology to deactivate the glutamine synthetase gene in Lonza’s host cell line CHOK1SV.
Lonza’s GS System™ technology uses selection via glutamine metabolism to generate high-yielding, stable cell lines. The firm claims hundreds of cell lines using the GS System have already been created to generate therapeutic proteins for clinical trials and commercial supply.
It maintains removal of the cell-based GS activity will enable further improvements to the selection process for creating recombinant cell lines. Cellectis specializes in the development of research tools for genome customization based on its meganuclease technology. Commercial products include its cGPS® System and cGPS Custom System kits for engineering specific cell lines.